康宁杰瑞制药-BKN026、JSKN003 ESMO数据惊艳,创新管线进入收获期

兴业证券
Nov 11, 2025

投资要点:公司具备高度差异化的在研管线,双抗与ADC品种全面布局。公司在ADC、双特异性抗体及多功能蛋白质工程方面拥有完善的专有技术平台,其中KN026与JSKN003已处于关键临床及申报上市阶段。公司具备基于结构的蛋白质工程能力,自主研发的专有平台包括sdAb平台、CRIB((荷排斥优化双特异性抗体)平台、糖基定点偶联平台、连接子-载荷平台、双载荷偶联平台等,具备行业领先的研发、生产、制造能力。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10